|
Fast Track Action Committee on Biosafety and Biosecurity
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP, NIAID
|
This Committee examines relevant biosafety regulations and further explores other options for biosafety oversight.
|
|
FDA Acute Radiation Syndrome (ARS) Action Team
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIAID
|
The purpose of this collaboration is to inform members of the FDA ARS Action Team on key data from the radiation and nuclear countermeasures program (RNCP) drug development portfolio that will inform them in advancing products that may be brought forward for eventual licensure. A biweekly meeting takes place between NIAID (RNCP/Program Officer) and FDA (OCET/Senior Advisor) Senior Advisor to decide which MCMs will be presented to the Action Team.
|
|
FDA Cancer Imaging Program (CIP) Bi-annual Meeting
|
Meeting/ Workshop
|
FDA
|
NCI
|
This collaboration is a bi-annual meeting to enhance communication between the Cancer Imaging Program (CIP) and the Division of Medical Imaging Products of CDER in the FDA. This allows for a two-way exchange of information and discussion of issues that are important for each side. Topics that have been discussed include CIP''s standardization efforts of medical imaging scanners in NCI Cancer Centers, presentation and discussion of specific new molecular imaging modalities, and discussion of recent FDA decisions regarding new medical imaging innovations.
|
|
FDA Microbiology Devices Panel of the Medical Devices Advisory Committee
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIAID
|
This Committee provides expertise in the evaluation of evidence submitted by pharmaceutical companies to the FDA for drug approval.
|
|
FDA Substance Registry System Public Interface
|
Resource Development
|
FDA
|
NLM
|
The National Library of Medicine (NLM) and the Food and Drug Administration (FDA) established a collaborative effort to provide an interface for public access to the FDA’s Substance Registration System (SRS). The FDA SRS utilizes an existing NLM database backend architecture to provide public search capability for FDA substances and medicinal products.
|
|
FDA-NCI Every Other Month Meeting
|
Meeting/ Workshop
|
FDA
|
NCI
|
An every other month meeting to enhance communication between NCI and FDA, thereby expediting the development of new anti-cancer agents. General topics discussed include patient safety, clinical efficacy, and regulatory pathways to licensure, as well as an understanding of the operations of the sister agencies.
|
|
FDA/NIH Interagency Clinical Outcomes Assessments Working Group Meeting
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIMH, NCCIH, NCI, NHLBI, NIAMS, NINDS
|
The FDA and Institute representatives from NIH meet periodically to discuss the development of valid patient-oriented treatment outcomes, and relative measurements, for use in clinical trials of therapeutic interventions.
|
|
Federal Breastfeeding Working Group
|
Committee, Work group, Advisory group, or Task Force
|
ACF, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, OSG
|
NICHD, NCI, NHLBI, NIDDK, NIEHS
|
The purpose of this workgroup is to develop strategies to implement the Surgeon General’s call to action to support breastfeeding.
|
|
Federal Consortium on the Substance Abusing Offender
|
Committee, Work group, Advisory group, or Task Force
|
SAMHSA
|
NIDA
|
Coordination of approximately a dozen agencies that work with substance abusing offenders. Staff meet by phone quarterly to provide updates on projects and initiatives at their agencies at the intersection of substance use and justice.
|
|
Federal Dietary Reference Intakes Steering Committee
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA, OS
|
NIDDK, NHLBI, OD/DPCPSI/ODS
|
This committee serves as an interagency forum to provide oversight on the process used to establish the Dietary Reference Intakes. These values serve as a basis for many federal nutrition programs and policies.
|